Hepatitis B virus vaccine

ApprovedVaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Hepatitis B virus vaccine is one of 64 biologic programs targeting Intestinal Schistosomiasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal SchistosomiasisActive, not recruiting

Hepatitis BActive, not recruiting

GrowthActive, not recruiting

Intestinal SchistosomiasisPhase 1

Active, not recruiting

Hepatitis BApproved

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Hepatitis B virus vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Aricept

Eisai

Preclinical

1 8

Somavaratan

Herceptin

4 10

Glucophage

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Post-ApprovalNot yet recruiting

Hepatitis B

NCT06786429

Clinical

Trials by Indication[1]

Hepatitis B4 trials

Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00100633·30 enrolled

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00272493·48 enrolled

Evaluation of the Efficacy of Cryotherapy Combined With Intralesional Hepatitis B Virus Vaccine Versus Either Therapy in the Treatment of Multiple Cutaneous Warts :a Comparative Study

Not yet recruiting·—·Phase 1·NCT05902624·60 enrolled

Show 1 more trial

Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.

Not yet recruiting·EEunice Dube·Phase 4·NCT06786429·1,800 enrolled

Growth1 trial

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00050921·60 enrolled

Intestinal Schistosomiasis1 trial

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03110757·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Hepatitis B virus vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hepatitis B virus vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hepatitis B virus vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Hepatitis B virus vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Hepatitis B4 trials

Growth1 trial

Intestinal Schistosomiasis1 trial

References

Drug Info

Quick Facts

Related News